Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
But there are no efficacy data, and the mechanism has a mountain to climb.
CRB-601 and PF-06940434 fall by the wayside.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
